The UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization in Great Britain for Cibinqo (abrocitinib), an oral, once-daily, Janus kinase 1 (JAK1) inhibitor.
Developed by US pharma giant Pfizer (NYSE: PFE), Cibinqo is approved for the treatment of moderate to severe atopic dermatitis (AD) in adults and adolescents aged 12 years and over, who are candidates for systemic therapy. Abrocitinib is licensed in recommended doses of 100mg and 200mg.
This is the first marketing authorization in the world for this treatment, Pfizer noted.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze